|Articles|May 21, 2020

Contagion Live News Network: Our Upcoming June Print Edition & More

A brief summary of the latest infectious disease news.

Hello and thank you for joining Contagion. I’m here with a brief on our latest infectious disease clinical coverage:

Contagion’s June print edition is on its way. In his June letter, titled “COVID-19 Preprints: Reader, Beware”, our editor-in-chief Dr. Jason Gallagher explores the influence of preprints amid the ongoing rush to publish information during the coronavirus pandemic.

We also shared an interview with Dr. Vickie Mays, who uses her training in clinical psychology to provide insight on the long-term cognitive impact of the coronavirus pandemic and outbreak response. Dr. Mays has past experience with the HIV/AIDS epidemic as well as disaster recovery in the wake of Hurricane Katrina.

In pipeline news, the US has funded the Oxford COVID-19 vaccine to the tune of 1 billion dollars. The vaccine will be developed by AstraZeneca.

And lastly, Contagion editorial director Allie Ward sat down with our regular contributor, Dr. Saskia Popescu, an infection prevention epidemiologist, to talk all things COVID, with a particular emphasis on what she calls the “info-demic” — a battle for information that rages online during the world’s first social mediatized pandemic.

For more on these stories and the latest infectious disease news, visit contagionlive.com. Thanks for watching.


Related to this article

New Diagnositics for Legionella Pneumonia May Streamline Care Continuum
Reported cases of Legionnaires’ disease have been on the rise for the past decade, and identifying Legionella bacteria requires specialized testing in the microbiology lab. Here is a clinical overview of Legionella bacteria, including required testing, treatment, and reporting to public health officials.
REMAP-CAP and the Tamiflu “Pre-Release”: A Set-Up for Disaster
Preliminary REMAP-CAP data suggesting oseltamivir may increase mortality in critically ill ICU influenza patients has sparked polarized reactions, but clinicians should await the full peer-reviewed manuscript before drawing broad conclusions, since the signal comes from a narrow, severely ill population and may reflect a therapeutic window effect rather than a blanket lack of efficacy.